This is from back in December and set the choices facing SGYP and shareholders next week..
January May Determine The Fate Of Synergy Pharmaceuticals
Summary
January will be a critical month for Synergy.
The FDA will vote on indication expansion for Trulance and the company will have to prove that it has sufficient cash to qualify for the second tranche of a debt.
An expanded indication could prompt a buyout offer. Failure to set a clear course not involving further dilution could instigate a shareholder revolt.
Management has a lot to prove in January. External actors may soon get the scent of blood.
Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.